BUSPAR TAB 10MG TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

BUSPIRONE HYDROCHLORIDE

Disponible desde:

BRISTOL-MYERS SQUIBB CANADA

Código ATC:

N05BE01

Designación común internacional (DCI):

BUSPIRONE

Dosis:

10MG

formulario farmacéutico:

TABLET

Composición:

BUSPIRONE HYDROCHLORIDE 10MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

MISCELLANEOUS ANXIOLYTICS SEDATIVES AND HYPNOTICS

Resumen del producto:

Active ingredient group (AIG) number: 0116263001; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2010-11-12

Ficha técnica

PRODUCT MONOGRAPH
PR
BUSPAR*
(BUSPIRONE HYDROCHLORIDE)
TABLETS, 5 AND 10 MG
ANXIOLYTIC
Bristol-Myers Squibb Canada
2365 Cote de Liesse
Date of Preparation:
Montreal, Canada
October 29, 2004
H4N 2M7
Date of Revision:
*
TM of Mead Johnson & Company used under
licence by Bristol-Myers Squibb Canada
Control No.:
094863
1
PRODUCT MONOGRAPH
BUSPAR*
(BUSPIRONE HYDROCHLORIDE)
Tablets, 5 and 10 mg
THERAPEUTIC CLASSIFICATION
Anxiolytic
ACTION AND CLINICAL PHARMACOLOGY
Buspirone is a psychotropic drug with selective anxiolytic properties
which belongs chemically
to the class of compounds known as the azaspirodecanediones, not
chemically or
pharmacologically related to benzodiazepines, barbiturates, or other
known psychotropic
agents.
Buspirone shares some of the properties of the benzodiazepines and the
neuroleptics, as well
as demonstrating other pharmacological action. Buspirone attenuates
punishment suppressed
behaviour in animals and exerts a taming effect, but is devoid of
anticonvulsant and muscle
relaxant properties and does not bind to the benzodiazepine/GABA
receptor complex.
Buspirone affects a variety of dopamine mediated biochemical and
behavioural events, but is
free of cataleptic activity. Buspirone has an affinity for brain D
2
-dopamine receptors, where it
acts as an antagonist and agonist, and for the 5-HT
1A
receptors, where it acts as an agonist.
Buspirone does not block the neuronal reuptake of monoamines and, on
chronic administration,
it does not lead to changes in receptor density in the models
investigated. However, the
mechanism of action of buspirone in man remains to be elucidated.
Buspirone is rapidly absorbed in man and undergoes extensive first
pass metabolism.
Following oral administration, low peak plasma levels of unchanged
drug, of 1 to 6 ng/mL were
observed 40 to 90 minutes after a single 20 mg dose. In a number of
studies performed in
healthy volunteers, the mean half-life of buspirone ranged from 2 to 3
hours up to approximately
11 hours with considerable variation in individual values.